Patents Examined by Gailene R. Gabel
-
Patent number: 7919266Abstract: A process for the detection of antibodies in a test sample by preparing a suspension of erythrocytes with a test serum or plasma by mixing a test serum or plasma with erythrocytes; incubating the suspension of erythrocytes at a temperature of from 37° C. to 45° C. to bind any antibodies in the test serum or plasma to the surface of said erythrocytes; combining the suspension of erythrocytes with an amount of a solution of a macromolecule which is effective to agglutinate the erythrocytes; packing the resultant red cell agglutinates by centrifuging the suspension of erythrocytes; and, determining the presence of anti-erythrocyte antibodies by observing if antibody-dependent erythrocyte agglutination has occurred.Type: GrantFiled: April 23, 2008Date of Patent: April 5, 2011Assignee: Clavina Diagnostics, Inc.Inventor: Parviz Lalezari
-
Patent number: 7915052Abstract: The present invention is related to immunoglobulin peptides that recognize a thermostable antigen from bovine blood. The invention also provides methods for determining the presence of bovine blood in a food sample or an animal feed sample.Type: GrantFiled: February 25, 2010Date of Patent: March 29, 2011Assignee: Florida State University Research Foundation, Inc.Inventor: Yun-Hwa Peggy Hsieh
-
Patent number: 7915001Abstract: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.Type: GrantFiled: June 27, 2008Date of Patent: March 29, 2011Assignee: Universite De LiegeInventors: Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
-
Patent number: 7910378Abstract: Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium. The combination comprises (i) the sample, (ii) a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and (iii) a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent comprises a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further comprise a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties.Type: GrantFiled: December 14, 2007Date of Patent: March 22, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Tie Q. Wei, Alan R. Craig, Amy Posey
-
Patent number: 7906295Abstract: A rapid method for the quantitation of various live cell types is described. This new cell fluorescence method correlates with other methods of enumerating cells such as the standard plate count, the methylene blue method and the slide viability technique. The method is particularly useful in several applications such as: a) quantitating bacteria in milk, yogurt, cheese, meat and other foods, b) quantitating yeast cells in brewing, fermentation and bread making, c) quantitating mammalian cells in research, food and clinical settings. The method is especially useful when both total and viable cell counts are required such as in the brewing industry. The method can also be employed to determine the metabolic activity of cells in a sample. The apparatus, device, and/or system used for cell quantitation is also disclosed.Type: GrantFiled: December 19, 2008Date of Patent: March 15, 2011Assignee: GenPrime, Inc.Inventors: James E. Fleming, Jason Buck Somes, Darby McLean, Jerad R. Holcomb
-
Patent number: 7901950Abstract: Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.Type: GrantFiled: February 2, 2007Date of Patent: March 8, 2011Assignee: Veridex, LLCInventors: Mark Carle Connelly, Gerald V. Doyle, Galla Chandra Rao, Leon W. M. M. Terstappen
-
Patent number: 7897328Abstract: The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.Type: GrantFiled: March 23, 2007Date of Patent: March 1, 2011Assignee: AbSorber ABInventors: Jan Holgersson, Jining Liu, Linda Lindberg, Per Grufman
-
Patent number: 7892842Abstract: The present application relates to procedures for the determination of the activity of the protease which activates factor VII, also known as factor VII activating protease or FSAP. The application also relates to a method of detecting whether an individual has increased or lowered activity in the protease which activates factor VII compared to at least one standard sample, wherein the increased or lowered activity indicates an increased risk for disease or cardiovascular complications.Type: GrantFiled: June 6, 2008Date of Patent: February 22, 2011Assignee: CSL Behring GmbHInventors: Juergen Roemisch, Annette Feussner, Hans-Arnold Stoehr
-
Patent number: 7888053Abstract: Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum/plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.Type: GrantFiled: August 31, 2009Date of Patent: February 15, 2011Assignee: BioArray Solutions, LLCInventor: Sukanta Banerjee
-
Patent number: 7883861Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.Type: GrantFiled: March 17, 2008Date of Patent: February 8, 2011Assignee: HemoGenix, Inc.Inventor: Ivan N. Rich
-
Patent number: 7879569Abstract: The present invention relates to methods and kits for diagnosing, ascertaining the clinical course a of myelodysplastic syndrome(MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides method and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.Type: GrantFiled: November 7, 2005Date of Patent: February 1, 2011Assignee: The Trustees of the University of PennsylvaniaInventors: Jonni Moore, Sindhu Cherian, Adam Bagg
-
Patent number: 7871813Abstract: A method of separating a cell-containing sample into a substantially cell-depleted portion, and a cell-containing portion comprising at least one of a stem cell, a lymphocyte, and a leukocyte comprises a step in which the sample is received in a vessel with at least one flexible wall. In another step, an additive and particles are added to the sample, wherein the additive substantially binds to the at least one of the stem cell, lymphocyte, and leukocyte, and the particles and wherein the particles substantially bind to the at least one of the stem cell, lymphocyte, and leukocyte, and the additive, thereby producing a cell-containing network. In a further step, the network is separated from the substantially cell-depleted portion by applying a magnetic force.Type: GrantFiled: March 24, 2008Date of Patent: January 18, 2011Assignee: Qualigen, Inc.Inventors: James Wyatt, Matthew Scott, Vijay K Mahant
-
Patent number: 7867447Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.Type: GrantFiled: July 22, 2008Date of Patent: January 11, 2011Assignee: Litron Laboratories, Ltd.Inventor: Stephen D. Dertinger
-
Patent number: 7863012Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: GrantFiled: February 17, 2004Date of Patent: January 4, 2011Assignee: Veridex, LLCInventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
-
Patent number: 7863047Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: April 25, 2008Date of Patent: January 4, 2011Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7858385Abstract: Method for detecting binding events using micro-X-ray fluorescence spectrometry. Receptors are exposed to at least one potential binder and arrayed on a substrate support. Each member of the array is exposed to X-ray radiation. The magnitude of a detectable X-ray fluorescence signal for at least one element can be used to determine whether a binding event between a binder and a receptor has occurred, and can provide information related to the extent of binding between the binder and receptor.Type: GrantFiled: May 16, 2001Date of Patent: December 28, 2010Assignee: Los Alamos National Security, LLCInventors: Benjamin P. Warner, George J. Havrilla, Grace Mann
-
Patent number: 7858757Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.Type: GrantFiled: March 31, 2005Date of Patent: December 28, 2010Assignee: Adnagen AGInventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
-
Patent number: 7855079Abstract: The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase, and peroxidase. The invention provides kits for performing the methods of the invention.Type: GrantFiled: July 25, 2007Date of Patent: December 21, 2010Assignee: General AtomicsInventors: Chong-Sheng Yuan, Abhijit Datta, Limin Liu
-
Patent number: 7842244Abstract: The present invention, provides a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles. The present invention also provides a flow cytometry method employing such an apparatus.Type: GrantFiled: May 5, 2008Date of Patent: November 30, 2010Assignee: STC.UNMInventors: Larry A. Sklar, Bruce S. Edwards, Frederick W. Kuckuck
-
Patent number: 7838284Abstract: Free-standing microfluidic channels are used to both transport and analyze molecules of interest. In a biochemical context, such molecules may be polypeptides, nucleic acids, or other biomolecules. The free-standing channels provide a real-time readout of concentration without the need for labeling with reporter molecules. The channels can also measure enthalpy values and equilibrium constants by detecting heat released from or absorbed by the sample.Type: GrantFiled: June 16, 2008Date of Patent: November 23, 2010Assignee: Massachusetts Institute of TechnologyInventor: Scott Manalis